1-15 of 15
Nirali N. Shah
Close
Sort by
Journal Articles

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults

Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M. Hsieh, Kevin McNerney, Rayne H. Rouce, Rebecca A. Gardner, Sara Ghorashian, Nirali N. Shah, Shannon L. Maude
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3544–3548.
https://doi.org/10.1182/bloodadvances.2024013243
Published: 2024
Journal Articles

CAR T cell Toxicities: Bedside to Bench - How Novel Toxicities Inform Laboratory Investigations

Clinical Trials & Observations
Fabiana Perna, Samir Parekh, Caroline Diorio, Melody Smith, Marion Subklewe, Rakesh Mehta, Frederick L Locke, Nirali N Shah
Journal: Blood Advances
Blood Adv bloodadvances.2024013044.
https://doi.org/10.1182/bloodadvances.2024013044
Published: 2024
Journal Articles

Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities

Clinical Trials & Observations
Joseph M. Rocco, Jon Inglefield, Bonnie Yates, Daniel A. Lichtenstein, Yanyu Wang, Laurence Goffin, Djordje Filipovic, Eduardo J. Schiffrin, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6134–6139.
https://doi.org/10.1182/bloodadvances.2023010708
Published: 2023
Includes: Supplemental data
Journal Articles

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials

Clinical Trials & Observations
Sara K. Silbert, Sanna Madan, Elizabeth M. Holland, Seth M. Steinberg, Lauren Little, Toni Foley, Monica Epstein, Angela Sarkisian, Daniel W. Lee, Ekaterina Nikitina, Showri Kakumanu, Eytan Ruppin, Haneen Shalabi, Bonnie Yates, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5566–5578.
https://doi.org/10.1182/bloodadvances.2023009789
Published: 2023
Includes: Supplemental data
Journal Articles

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

Adam J. Lamble, Regina M. Myers, Agne Taraseviciute, Samuel John, Bonnie Yates, Seth M. Steinberg, Jennifer Sheppard, Alexandra E. Kovach, Brent Wood, Michael J. Borowitz, Maryalice Stetler-Stevenson, Constance M. Yuan, Vinodh Pillai, Toni Foley, Perry Chung, Lee Chen, Daniel W. Lee, Colleen Annesley, Amanda DiNofia, Stephan A. Grupp, Michael R. Verneris, Lia Gore, Theodore W. Laetsch, Deepa Bhojwani, Patrick A. Brown, Michael A. Pulsipher, Susan R. Rheingold, Rebecca A. Gardner, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2023) 7 (4): 575–585.
https://doi.org/10.1182/bloodadvances.2022007423
Published: 2023
Includes: Supplemental data
Journal Articles

CD22 low /Bcl-2 high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

Clinical Trials & Observations
Astrid Wintering, Kenichi Ishiyama, Stanley Tamaki, Courtney Tamaki, Joshua Fandel, Lingyun Ji, Brent L. Wood, Nirali N. Shah, Constance M. Yuan, Maureen M. O’Brien, Mignon L. Loh, Ernesto Diaz-Flores
Journal: Blood Advances
Blood Adv (2023) 7 (2): 251–255.
https://doi.org/10.1182/bloodadvances.2021006810
Published: 2023
Includes: Supplemental data
Journal Articles

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes

Clinical Trials & Observations
Aiman J. Faruqi, John A. Ligon, Paul Borgman, Seth M. Steinberg, Toni Foley, Lauren Little, Crystal L. Mackall, Daniel W. Lee, Terry J. Fry, Haneen Shalabi, Jennifer Brudno, Bonnie Yates, Lekha Mikkilineni, James Kochenderfer, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2022) 6 (23): 6040–6050.
https://doi.org/10.1182/bloodadvances.2022007676
Published: 2022
Includes: Supplemental data
Journal Articles

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Emily M. Hsieh, Regina M. Myers, Bonnie Yates, Colleen Annesley, Samuel John, Agne Taraseviciute, Seth M. Steinberg, Jennifer Sheppard, Perry Chung, Lee Chen, Daniel W. Lee, Amanda DiNofia, Stephan A. Grupp, Michael R. Verneris, Theodore W. Laetsch, Deepa Bhojwani, Patrick A. Brown, Michael A. Pulsipher, Susan R. Rheingold, Rebecca A. Gardner, Lia Gore, Nirali N. Shah, Adam J. Lamble
Journal: Blood Advances
Blood Adv (2022) 6 (17): 5222–5226.
https://doi.org/10.1182/bloodadvances.2022008093
Published: 2022
Journal Articles

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities

Caroline Diorio, Anant Vatsayan, Aimee C. Talleur, Colleen Annesley, Jennifer J. Jaroscak, Haneen Shalabi, Amanda K. Ombrello, Michelle Hudspeth, Shannon L. Maude, Rebecca A. Gardner, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3398–3403.
https://doi.org/10.1182/bloodadvances.2022006983
Published: 2022
Includes: Supplemental data
Journal Articles

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy

Clinical Trials & Observations
Elizabeth M. Holland, Bonnie Yates, Alex Ling, Constance M. Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Michael LaLoggia, John C. Molina, Daniel A. Lichtenstein, Daniel W. Lee, John A. Ligon, Haneen Shalabi, Mark A. Ahlman, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2167–2182.
https://doi.org/10.1182/bloodadvances.2021006035
Published: 2022
Includes: Supplemental data
Journal Articles

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

Clinical Trials & Observations
Lekha Mikkilineni, Bonnie Yates, Seth M. Steinberg, Shilpa A. Shahani, John C. Molina, Tara Palmore, Daniel W. Lee, Rosandra N. Kaplan, Crystal L. Mackall, Terry J. Fry, Juan Gea-Banacloche, Theresa Jerussi, Veronique Nussenblatt, James N. Kochenderfer, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5312–5322.
https://doi.org/10.1182/bloodadvances.2021004896
Published: 2021
Includes: Supplemental data
Journal Articles

CAR T cells better than BiTEs

Clinical Trials & Observations
John C. Molina, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2021) 5 (2): 602–606.
https://doi.org/10.1182/bloodadvances.2020003554
Published: 2021
Journal Articles

Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield

Nosha Farhadfar, Jack W. Hsu, Brent R. Logan, Jennifer A. Sees, Pintip Chitphakdithai, Michele W. Sugrue, Hisham Abdel-Azim, Paolo N. Anderlini, Christopher Bredeson, Saurabh Chhabra, Miguel Angel Diaz, Siddhartha Ganguly, Peiman Hematti, Rammurti T. Kamble, Kimberly A. Kasow, Hillard M. Lazarus, Debra Kelly Lynch, Hemant S. Murthy, Richard F. Olsson, Mona Papari, Donna Przepiorka, Bipin N. Savani, Raquel Schears, Sachiko Seo, Melhem M. Solh, Thomas Spitzer, Jean A. Yared, Michael A. Pulsipher, Nirali N. Shah, Galen E. Switzer, Dennis L. Confer, Bronwen E. Shaw, John R. Wingard
Journal: Blood Advances
Blood Adv (2020) 4 (4): 706–716.
https://doi.org/10.1182/bloodadvances.2019000923
Published: 2020
Includes: Supplemental data
Journal Articles

More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling

Peter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E. Woolfrey, Merav Bar, Michael R. Verneris, Michael J. Borowitz, Nirali N. Shah, Nathan Gossai, Peter J. Shaw, Allen R. Chen, Kirk R. Schultz, Hermann Kreyenberg, Lucia Di Maio, Gianni Cazzaniga, Cornelia Eckert, Vincent H. J. van der Velden, Rosemary Sutton, Arjan Lankester, Christina Peters, Thomas E. Klingebiel, Andre M. Willasch, Stephan A. Grupp, Michael A. Pulsipher
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3393–3405.
https://doi.org/10.1182/bloodadvances.2019000449
Published: 2019
Includes: Supplemental data
Journal Articles

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy

Clinical Trials & Observations
Nirali N. Shah, Haiying Qin, Bonnie Yates, Ling Su, Haneen Shalabi, Mark Raffeld, Mark A. Ahlman, Maryalice Stetler-Stevenson, Constance Yuan, Shuang Guo, Siyuan Liu, Stephen H. Hughes, Terry J. Fry, Xiaolin Wu
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2317–2322.
https://doi.org/10.1182/bloodadvances.2019000219
Published: 2019